[go: up one dir, main page]

MX2024006771A - Forma cristalina de n-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-dihid roquinazolin-6-il)amino)-4-fluorofenil)-3-fluoroazetidina-1-sulfo namida. - Google Patents

Forma cristalina de n-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-dihid roquinazolin-6-il)amino)-4-fluorofenil)-3-fluoroazetidina-1-sulfo namida.

Info

Publication number
MX2024006771A
MX2024006771A MX2024006771A MX2024006771A MX2024006771A MX 2024006771 A MX2024006771 A MX 2024006771A MX 2024006771 A MX2024006771 A MX 2024006771A MX 2024006771 A MX2024006771 A MX 2024006771A MX 2024006771 A MX2024006771 A MX 2024006771A
Authority
MX
Mexico
Prior art keywords
chloro
crystalline form
fluoroazetidine
fluorophenyl
oxo
Prior art date
Application number
MX2024006771A
Other languages
English (en)
Inventor
Connor James Cowdrey
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2024006771A publication Critical patent/MX2024006771A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a una forma cristalina de N-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-dihidroquinazolin-6-il)a mino)-4-fluorofenil)-3-fluoroazetidina-1-sulfonamida, composiciones farmacéuticas que comprenden dicha forma cristalina y métodos para usar dicha forma cristalina en el tratamiento de enfermedades y trastornos asociados a BRAF, tales como tumores asociados a BRAF.
MX2024006771A 2021-12-08 2022-12-02 Forma cristalina de n-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-dihid roquinazolin-6-il)amino)-4-fluorofenil)-3-fluoroazetidina-1-sulfo namida. MX2024006771A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163287127P 2021-12-08 2021-12-08
US202263393043P 2022-07-28 2022-07-28
PCT/IB2022/061716 WO2023105371A1 (en) 2021-12-08 2022-12-02 Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide

Publications (1)

Publication Number Publication Date
MX2024006771A true MX2024006771A (es) 2024-06-20

Family

ID=84488838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006771A MX2024006771A (es) 2021-12-08 2022-12-02 Forma cristalina de n-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-dihid roquinazolin-6-il)amino)-4-fluorofenil)-3-fluoroazetidina-1-sulfo namida.

Country Status (9)

Country Link
US (1) US20250011304A1 (es)
EP (1) EP4444710A1 (es)
JP (1) JP2024545073A (es)
KR (1) KR20240115893A (es)
AU (1) AU2022403854B2 (es)
CA (1) CA3241856A1 (es)
MX (1) MX2024006771A (es)
TW (1) TWI836777B (es)
WO (1) WO2023105371A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4073065T (pt) 2019-12-10 2025-04-15 Hoffmann La Roche Novos derivados de metilquinazolinona
IL308748A (en) 2021-06-08 2024-01-01 C4 Therapeutics Inc Therapeutic agents for knockdown of mutant BRAF
WO2025153057A1 (zh) * 2024-01-17 2025-07-24 海思科医药集团股份有限公司 一种含braf抑制剂的药物组合物及其在医药上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
US10898487B2 (en) 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
TR201914039A2 (tr) 2019-09-16 2021-04-21 Univ Istanbul Teknik Ses veri̇leri̇ etki̇leşi̇mli̇ di̇nami̇k adapti̇f cephe modülü si̇stemi̇
KR102904179B1 (ko) * 2020-06-09 2025-12-26 어레이 바이오파마 인크. Braf-관련 질환 및 장애의 치료를 위한 4-옥소-3,4-다이하이드로퀸아졸린온 화합물

Also Published As

Publication number Publication date
JP2024545073A (ja) 2024-12-05
EP4444710A1 (en) 2024-10-16
AU2022403854A1 (en) 2024-05-23
US20250011304A1 (en) 2025-01-09
TW202330503A (zh) 2023-08-01
KR20240115893A (ko) 2024-07-26
AU2022403854B2 (en) 2025-04-17
TWI836777B (zh) 2024-03-21
WO2023105371A1 (en) 2023-06-15
CA3241856A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
MX2024006771A (es) Forma cristalina de n-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-dihid roquinazolin-6-il)amino)-4-fluorofenil)-3-fluoroazetidina-1-sulfo namida.
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
SA522432518B1 (ar) مركبات أريل غير متجانسة ثنائية الحلقة واستخداماتها
MY209609A (en) Immunomodulators, compositions and methods thereof
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
PH12017500725B1 (en) Indole carboxamide compounds useful as kinase inhibitors
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
MX379543B (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
EA200801711A1 (ru) Пролекарства возбуждающих аминокислот
PH12019501896A1 (en) Therapeutic dendrimers
MX2018010983A (es) Derivado de 3-desoxi y composiciones farmaceuticas del mismo.
EA201990400A1 (ru) Соединения и композиции и их применение
PH12021550368A1 (en) Dimethyl amino azetidine amides as jak inhibitors
TN2017000158A1 (en) Carbazole derivatives
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
BR112023018237A2 (pt) Fenalquilaminas e métodos para fabricação e uso das mesmas
SA522441554B1 (ar) Ripk1 مركبات أيزوكسازوليدين كمثبطات واستخدامها
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
EA201992744A1 (ru) Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей
ATE410408T1 (de) Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon